

		EMLc	ATC codes: <b>V03AB09</b>
Indication	Harmful effects of or exposure to noxious substances, chiefly nonmedicinal as to source, not elsewhere classified <span style="background-color: #0070C0; color: white; padding: 2px;">ICD11 code: <b>NE61</b></span>		
INN	Dimercaprol		
Medicine type	Chemical agent		
List type	Complementary (EML) (EMLc)		
Formulations	Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule ; 100 mg per mL in 3 mL ampoule		
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2011 ( <a href="#">TRS 965</a> ) Changed in 2025 ( <a href="#">TRS 1064</a> )		
Sex	All		
Age	Also recommended for children		
Therapeutic alternatives	The recommendation is for this specific medicine		
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
Wikipedia	<a href="#">Dimercaprol</a> 		
DrugBank	<a href="#">Dimercaprol</a> 		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of 100 mg/mL dimercaprol injection in oil to the EML and EMLc.

